Eicosatetraynoic Acid and Butyrate Regulate Human Intestinal Organoid Mitochondrial and Extracellular Matrix Pathways Implicated in Crohn's Disease Strictures.
NADPH oxidase
fibrosis
reactive oxygen species
small molecule
Journal
Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162
Informations de publication
Date de publication:
01 07 2022
01 07 2022
Historique:
received:
25
01
2022
pubmed:
9
3
2022
medline:
6
7
2022
entrez:
8
3
2022
Statut:
ppublish
Résumé
Perturbagen analysis of Crohn's disease (CD) ileal gene expression data identified small molecules including eicosatetraynoic acid (ETYA), which may exert an antifibrotic effect. We developed a patient-specific human intestinal organoid (HIO) model system to test small molecule regulation of mitochondrial and wound-healing functions implicated in stricturing behavior. HIOs were made from CD induced pluripotent stem cells with and without a loss-of-function haplotype in the DUOX2 gene implicated in ileal homeostasis and characterized under basal conditions and following exposure to butyrate and ETYA using RNA sequencing, flow cytometry, and immunofluorescent and polarized light microscopy. Mitochondrial activity was measured using high-resolution respirometry and tissue stiffness using atomic force microscopy. HIOs expressed core mitochondrial and extracellular matrix (ECM) genes and enriched biologic functions implicated in CD ileal strictures; ECM gene expression was suppressed by both butyrate and ETYA, with butyrate also suppressing genes regulating epithelial proliferation. Consistent with this, butyrate, but not ETYA, exerted a profound effect on HIO epithelial mitochondrial function, reactive oxygen species production, and cellular abundance. Butyrate and ETYA suppressed HIO expression of alpha smooth muscle actin expressed by myofibroblasts, type I collagen, and collagen protein abundance. HIOs exhibited tissue stiffness comparable to normal human ileum; this was reduced by chronic ETYA exposure in HIOs carrying the DUOX2 loss-of-function haplotype. ETYA regulates ECM genes implicated in strictures and suppresses collagen content and tissue stiffness in an HIO model. HIOs provide a platform to test personalized therapeutics, including small molecules prioritized by perturbagen analysis. A subset of pediatric Crohn’s disease patients develop intestinal strictures requiring surgery. The microbial metabolite butyrate and eicosatetraynoic acid regulate pathways implicated in stricture formation in a human intestinal organoid model system, which may be used to test new therapies.
Sections du résumé
BACKGROUND
Perturbagen analysis of Crohn's disease (CD) ileal gene expression data identified small molecules including eicosatetraynoic acid (ETYA), which may exert an antifibrotic effect. We developed a patient-specific human intestinal organoid (HIO) model system to test small molecule regulation of mitochondrial and wound-healing functions implicated in stricturing behavior.
METHODS
HIOs were made from CD induced pluripotent stem cells with and without a loss-of-function haplotype in the DUOX2 gene implicated in ileal homeostasis and characterized under basal conditions and following exposure to butyrate and ETYA using RNA sequencing, flow cytometry, and immunofluorescent and polarized light microscopy. Mitochondrial activity was measured using high-resolution respirometry and tissue stiffness using atomic force microscopy.
RESULTS
HIOs expressed core mitochondrial and extracellular matrix (ECM) genes and enriched biologic functions implicated in CD ileal strictures; ECM gene expression was suppressed by both butyrate and ETYA, with butyrate also suppressing genes regulating epithelial proliferation. Consistent with this, butyrate, but not ETYA, exerted a profound effect on HIO epithelial mitochondrial function, reactive oxygen species production, and cellular abundance. Butyrate and ETYA suppressed HIO expression of alpha smooth muscle actin expressed by myofibroblasts, type I collagen, and collagen protein abundance. HIOs exhibited tissue stiffness comparable to normal human ileum; this was reduced by chronic ETYA exposure in HIOs carrying the DUOX2 loss-of-function haplotype.
CONCLUSIONS
ETYA regulates ECM genes implicated in strictures and suppresses collagen content and tissue stiffness in an HIO model. HIOs provide a platform to test personalized therapeutics, including small molecules prioritized by perturbagen analysis.
A subset of pediatric Crohn’s disease patients develop intestinal strictures requiring surgery. The microbial metabolite butyrate and eicosatetraynoic acid regulate pathways implicated in stricture formation in a human intestinal organoid model system, which may be used to test new therapies.
Autres résumés
Type: plain-language-summary
(eng)
A subset of pediatric Crohn’s disease patients develop intestinal strictures requiring surgery. The microbial metabolite butyrate and eicosatetraynoic acid regulate pathways implicated in stricture formation in a human intestinal organoid model system, which may be used to test new therapies.
Identifiants
pubmed: 35259271
pii: 6544735
doi: 10.1093/ibd/izac037
pmc: PMC9247849
doi:
Substances chimiques
Butyrates
0
Collagen
9007-34-5
Dual Oxidases
EC 1.11.1.-
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
988-1003Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK078392
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK120986
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
PLoS One. 2020 Aug 27;15(8):e0237885
pubmed: 32853234
Thromb Haemost. 2006 Nov;96(5):652-9
pubmed: 17080223
Nucleic Acids Res. 2010 Jul;38(Web Server issue):W96-102
pubmed: 20484371
Cell Mol Gastroenterol Hepatol. 2021;11(2):551-571
pubmed: 32992049
Gastroenterology. 2017 Jan;152(1):206-217.e2
pubmed: 27693347
Inflamm Res. 2018 Oct;67(10):829-837
pubmed: 30030553
Nature. 2014 Dec 18;516(7531):400-4
pubmed: 25363776
Gastroenterology. 2011 Sep;141(3):819-826.e1
pubmed: 21784048
World J Gastroenterol. 2012 Aug 28;18(32):4278-87
pubmed: 22969190
Inflamm Bowel Dis. 2022 May 4;28(5):667-679
pubmed: 34918082
Cancer Res. 2003 Oct 1;63(19):6311-9
pubmed: 14559818
Am J Physiol Cell Physiol. 2015 Sep 15;309(6):C350-60
pubmed: 26179603
Sci Rep. 2017 Oct 3;7(1):12569
pubmed: 28974751
Nature. 2011 Feb 3;470(7332):105-9
pubmed: 21151107
J Crohns Colitis. 2020 Aug 08;:
pubmed: 32770196
Neuromolecular Med. 2006;8(3):389-414
pubmed: 16775390
Gastroenterology. 2014 Feb;146(2):383-91
pubmed: 24162032
Gastroenterology. 2015 Dec;149(7):1849-59
pubmed: 26261005
Nat Commun. 2021 May 10;12(1):2595
pubmed: 33972536
JCI Insight. 2017 Feb 23;2(4):e91454
pubmed: 28239659
J Cell Sci. 2009 Oct 1;122(Pt 19):3522-30
pubmed: 19759286
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1799-1806
pubmed: 30213581
Cell Metab. 2019 Aug 6;30(2):374-384.e6
pubmed: 31155493
J Clin Invest. 2021 May 3;131(9):
pubmed: 33651715
Redox Biol. 2015 Dec;6:135-156
pubmed: 26210446
J Clin Invest. 2014 Aug;124(8):3617-33
pubmed: 25003194
Genes Immun. 2019 Feb;20(2):131-142
pubmed: 29593342
J Clin Endocrinol Metab. 2014 Mar;99(3):E544-53
pubmed: 24423310
Nat Protoc. 2011 Nov 10;6(12):1920-8
pubmed: 22082986
Exp Mol Pathol. 2015 Jun;98(3):346-51
pubmed: 25828392
Am J Physiol. 1997 Dec;273(6):L1249-57
pubmed: 9435581
Am J Gastroenterol. 2019 May;114(5):777-785
pubmed: 31058681
Am J Hum Genet. 2021 Mar 4;108(3):431-445
pubmed: 33600772
Trends Biotechnol. 2019 Jul;37(7):761-774
pubmed: 30654913
Lancet. 2017 Apr 29;389(10080):1710-1718
pubmed: 28259484
Front Immunol. 2019 Mar 11;10:277
pubmed: 30915065
Cell. 2019 Sep 5;178(6):1493-1508.e20
pubmed: 31474370